Business
Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)
ADELAIDE, Australia and CAMBRIDGE, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or the Company) a
About this update from Neuphoria Therapeutics Inc.
[{"type":"text","content":"ADELAIDE, Australia and CAMBRIDGE, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or the Company) a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it has submitted a formal request to the Australian Securities Exchange (“ASX”) to be removed from the official list of the ASX, in keeping with the Company’s ongoing transformation to a U.S. focused organization. The main consequence of an ASX delisting for shareholders is that, from the time the proposed ASX delisting is scheduled to take effect on August 28, 2023, Bionomics Shares will no longer be quoted or traded on the ASX, and will only be tradable in the form of American Depositary Shares on the NASDAQ Global Market (NASDAQ) under the symbol BNOX. “Bionomics is approaching several very important value-inflection milestones for our late-stage clinical development program with BNC210, a first and best-in class α7 nicotinic receptor negative allosteric modulator under evaluation in patients with Social Anxiety Disorder (SAD) and Post-Traumatic Stress Syndrome (PTSD), in the coming quarters,” said Spyros Papapetropoulos, M.D. Ph.D., Bionomics’ President and CEO; “As we continue our transformation to a U.S.-focused organization, we would like to deepen our engagement with the broadest range of potential investors and maximize Bionomics’ access to capital and financing opportunities while reducing costs and compliance obligations associated with a dual listing. We believe delisting from the ASX and focusing on a primary listing on the NASDAQ will increase our trading volume and liquidity, and consequently will enable Bionomics to fulfill these objectives and support continued value creation for patients, investors, and our stakeholders.” Additional announcements will be made to the ASX, and notices will be sent to shareholders on the Australian share register, outlining the proposed delisting process and timeline, and their available options. All information will be made available at https://ir.bionomics.com.au/. FOR FURTHER INFORMATION PLEASE CONTACT: GeneralInvestor RelationsInvestor RelationsMs. Suzanne IrwinKevin GardnerChris CalabreseCompany Secre...